LENZ Therapeutics, Inc. (LENZ)
Nasdaq: LENZ · Biological Products, (No Diagnostic Substances) · Solana Beach, CA · filing with the SEC since 2021
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Report filed | Mar 24, 2026 | Mar 19, 2025 | Feb 27, 2024 | Mar 20, 2023 | Mar 21, 2022 | · |
| Revenue | 19,088 | 0 | · | · | · | · |
| Cost of revenue | 418 | 0 | · | · | · | · |
| Research and development | 18,670 | 29,801 | 59,504r | 72,787 | 37,932 | 9,123 |
| Selling, general and administrative | 91,138 | 28,809 | 12,925 | · | · | · |
| General and administrative | · | · | 40,973 | 32,852 | 22,511 | 4,377 |
| Total operating expenses | · | 58,610 | 72,429r | 105,639 | 60,443 | 13,500 |
| Total costs and expenses | 110,226 | 58,610 | · | · | · | · |
| Operating income | -91,138 | -58,610 | -72,429r | -105,639 | -60,443 | -13,500 |
| Interest and investment income | 9,756 | 8,553 | 2,189 | · | · | · |
| Other income (expense), net | -243 | 289 | 93r | 4,587 | 24 | · |
| Total non-operating income (expense) | 9,513 | 8,842 | 2,282r | 4,587 | -10,317 | -54,873 |
| Income before income taxes | -81,625 | -49,768 | -70,147 | · | · | · |
| Income tax expense | 502 | 1 | -179 | 0 | 0 | 0 |
| Net income including non-controlling interests | · | · | -124,651 | -101,052 | -70,760 | -68,373 |
| Net income | -82,127 | -49,769 | -69,968r | -101,052 | -70,760 | -68,373 |
| Earnings per share, basic | -2.85 | -2.34 | -35.71r | -1.84 | -2.45 | · |
| Earnings per share, diluted | -2.85 | -2.34 | -35.71r | -1.84 | -2.45 | · |
| Earnings per share, basic and diluted | · | · | · | · | -2.45 | -29.93 |
| Weighted average shares, basic | 28,813,164 | 21,281,038 | 1,959,091r | 54,873,675 | 28,919,255 | · |
| Weighted average shares, diluted | 28,813,164 | 21,281,038 | 1,959,091r | 54,873,675 | 28,919,255 | · |
| Weighted average shares, basic and diluted | · | · | · | · | 28,919,255 | 2,284,087 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfGoodsAndServicesSoldResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesTotal costs and expenses every operating cost, the cost of revenue included
us-gaap:CostsAndExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted